Daily Bulletin

Men's Weekly

.

US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Cision

MELBOURNE, Australia, Sept. 15, 2021 /PRNewswire/ -- DEP® cabazitaxel is a proprietary nanoparticle version of leading prostate cancer drug cabazitaxel (Jevtana®), which had global sales of US$536 million in 2020. Starpharma's DEP® cabazitaxel is a water soluble, polysorbate-80 free formulation, without requirement for...

Read more: US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2...

Business News

Car Rental as a Practical and Flexible Solution for Travel or Work

The contemporary, hectic way of life is one of ease and adaptability while commuting and working. Regardless of whether one moves around by road, commuting between towns for conferences, or taking a f...

Daily Bulletin - avatar Daily Bulletin

Car Park Markings Melbourne: How Quality Line Marking Shapes Safer Spaces

In modern busy urbanized societies, structured parking areas are necessary in terms of both security and convenience. At a shopping center, business establishment, or a publicly-accessible facility, t...

Daily Bulletin - avatar Daily Bulletin

Cleaning Australia: The Rise of Professional Cleaning Services

The cleaning industry in Australia is booming as more people are opting for professional cleaning services to keep their homes, offices, and businesses spotless. With the increasing demand for cleanli...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business